On April 26, 2023 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that two abstracts with its innate cell engager (ICE) AFM24 have been accepted for the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 2 – 6, 2023 in Chicago, IL (Press release, Affimed, APR 26, 2023, View Source [SID1234630552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NSCLC Abstract and Presentation Details:
Title: Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort
Authors: Anthony B. El-Khoueiry, Delcia Rivas, Se Hoon Lee, Jacob Stephen Thomas, Yu Jung Kim, Andrés Cervantes, Omar Saavedra Santa Gadea, Byoung Yong Shim, Laura Kohlhas, Gabriele Hintzen, Michael Emig, Pilar Nava-Parada
Poster presentation session: Developmental Therapeutics—Immunotherapy, June 3, 2023, 8:00 – 11:00 a.m. CDT
Abstract Number for Publication: 2533

CRC Abstract Details:
Title: Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort
Authors: Andrés Cervantes, Delcia Rivas, Se Hoon Lee, Jacob Stephen Thomas, Yu Jung Kim, Omar Saavedra Santa Gadea, Byoung-Yong Shim, Laura Kohlhas, Gabriele Hintzen, Michael Emig, Pilar Nava-Parada, Anthony B. El-Khoueiry Abstract Number for Publication: e14508

The full abstracts will become public at 5:00 p.m. EDT on Thursday, May 25. More details about the programs for the ASCO (Free ASCO Whitepaper) Annual Meetings are available online at www.asco.com.

About AFM24
AFM24 is a tetravalent, bispecific innate cell engager (ICE) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Affimed is evaluating AFM24 as monotherapy and in combinations with other cancer treatments in patients with advanced EGFR-expressing solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24-101, a monotherapy, first-in-human phase 1/2a open-label, is a non-randomized, multi-center, multiple ascending dose escalation and expansion study. Additional details may be found at www.clinicaltrials.gov using the identifier NCT04259450. AFM24 is also being evaluated in a phase 1/2a study in combination with Roche’s PD-L1 checkpoint inhibitor atezolizumab (AFM24-102, NCT05109442). Furthermore, Affimed and NKGen Biotech initiated a phase 1/2a study (AFM24-103), investigating AFM24 in combination with NKGen Biotech’s NK cell SNK01 (NCT05099549).